arbiter
JournalsPricingAccount

Drug Competition:

Suchin Virabhak

Journal of Pharmaceutical Finance, Economics and Policy2007https://doi.org/10.1300/j371v15n02_02article
ABDC C
Weight
0.37

What the paper says

This paper examines generic competition following the enactment of the 1984Waxman-Hatch Act. Unlike the existing literature, we employ antibiotics as a control group to infer legislation-induced increases in generic competition. Using FDA drug approval data, we find evidence that the Act enhanced generic competition, resulting in 1.5 times more competition between nonantibiotic drugs than between antibiotics. Moreover, the Act's overall impact is greater for newer drugs than older drugs. Copyright © by The Haworth Press, Inc. All rights reserved.

1 citation

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1300/j371v15n02_02

Or copy a formatted citation

@article{suchin2007,
  title        = {{Drug Competition:}},
  author       = {Suchin Virabhak},
  journal      = {Journal of Pharmaceutical Finance, Economics and Policy},
  year         = {2007},
  doi          = {https://doi.org/https://doi.org/10.1300/j371v15n02_02},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Drug Competition:

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.37

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.30 × 0.4 = 0.12
M · momentum0.20 × 0.15 = 0.03
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.